Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | NOVO NORDISK | 11 | 40 | -0,31 % | |
| VESTAS WIND SYSTEMS | 3 | 9 | 0,00 % | |
| TRYG | 1 | - | +0,50 % | |
| AP MOELLER-MAERSK | - | 23 | +0,70 % | |
| ORSTED | - | 17 | +0,45 % | |
| DANSKE BANK | - | 10 | +0,67 % | |
| BAVARIAN NORDIC | - | 7 | -0,40 % | |
| DSV | - | 4 | -2,56 % | |
| ROCKWOOL | - | 4 | -0,08 % | |
| CARLSBERG | - | 3 | +0,46 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:48 | DSV Q1 Earnings Rise; Reiterates FY26 EBIT Outlook | 44 | AFX News | WASHINGTON (dpa-AFX) - DSV A/S (DSV.CO), a Danish transport and logistics company, on Wednesday reported higher net income in the first quarter of 2026 compared with the previous year. The company... ► Artikel lesen | |
| 08:30 | Was bei Novo nordisk gerade passiert: Was die wenigsten Anleger auf dem Schirm haben - Was erfahrene Trader jetzt tun! | Hebelschein-Spekulant | |||
| 06:18 | Kanada genehmigt erstes Generikum für Diabetes-Mittel Ozempic | 47 | cash | ||
| 03:51 | Abnehm-Medikament Ozempic: Novo Nordisk bekommt Konkurrenz | 39 | t-online.de | ||
| 00:19 | Health Canada approves first generic version of Ozempic | 25 | BNN Bloomberg | ||
| Di | Abnehmwunder made in Germany: Dieses deutsche Familienunternehmen will Novo und Lilly vom Thron stoßen | 2.795 | wallstreetONLINE | © Foto: Helmut Fricke - dpaNicht weniger Kilos, sondern bessere Kilos - das ist das Versprechen, mit dem Boehringer Ingelheim in den milliardenschweren Markt für Abnehmmittel drängt. Das Ingelheimer... ► Artikel lesen | |
| Di | Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth? | 34 | Zacks | ||
| Di | Novo Nordisk A/S: Novo Nordisk to present new data on Wegovy, women with obesity and next-generation weight loss treatments at European Congress on Obesity | 2.080 | GlobeNewswire (Europe) | Analyses of the higher dose of Wegovy (semaglutide 7.2 mg) and Wegovy pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achievedWegovy... ► Artikel lesen | |
| Di | NOVO NORDISK A/S - Stabilität mit strategischer Tiefe | 20 | Maximilian Berger | ||
| Di | Tryg A/S: Tryg recognises a one-off impact of DKK 1.2bn pre-tax related to Supreme Court ruling on Danish workers' compensation | 134 | GlobeNewswire (Europe) | Today, the Danish Supreme Court ruled on a precedent-setting case regarding workers' compensation in Denmark, which affects the entire insurance industry as well as the State and municipalities in Denmark.... ► Artikel lesen | |
| Di | Is This Deal a Game Changer for Novo Nordisk? | 90 | The Motley Fool | ||
| Di | Zealand Pharma: Survodutide erzielt 16,6 % Gewichtsverlust in Phase-III-Studie | 17 | Investing.com Deutsch | ||
| Di | Erfolg in Phase-3-Studie: Survodutid von Zealand Pharma erzielt 16,6 % Gewichtsverlust | 12 | Investing.com Deutsch | ||
| Di | Zealand Pharma's survodutide achieves 16.6% weight loss in trial | 3 | Investing.com | ||
| Di | Zealand Pharma's survodutide shows 16.6% weight loss in trial | 5 | Investing.com | ||
| Di | Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial | 373 | GlobeNewswire (Europe) | Company announcement - No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic... ► Artikel lesen | |
| Di | Central Vietnam hub Danang deepens cooperation with Maersk on Lien Chieu port, logistics | 2 | Theinvestor.vn | ||
| Mo | Prothena Corporation plc: Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy | 447 | Business Wire |
Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3
Coramitug is being evaluated by Novo Nordisk in the ongoing Phase... ► Artikel lesen | |
| Mo | Maersk lines up Med-Baltic SLA loop from Tanger Med | 4 | PortNews | ||
| Mo | Vestas wins 186MW Quebec turbine order | 10 | reNews |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.